AU2006291007A1 - 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase - Google Patents

5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase Download PDF

Info

Publication number
AU2006291007A1
AU2006291007A1 AU2006291007A AU2006291007A AU2006291007A1 AU 2006291007 A1 AU2006291007 A1 AU 2006291007A1 AU 2006291007 A AU2006291007 A AU 2006291007A AU 2006291007 A AU2006291007 A AU 2006291007A AU 2006291007 A1 AU2006291007 A1 AU 2006291007A1
Authority
AU
Australia
Prior art keywords
oxo
carboxylic acid
dihydro
pyrimidine
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006291007A
Other languages
English (en)
Inventor
Renee Desjarlais
Hui Huang
Daniel Hutta
Mark R. Player
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2006291007A1 publication Critical patent/AU2006291007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
AU2006291007A 2005-09-14 2006-09-13 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase Abandoned AU2006291007A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71452605P 2005-09-14 2005-09-14
US60/714,526 2005-09-14
PCT/US2006/035619 WO2007033232A1 (fr) 2005-09-14 2006-09-13 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de kinase c-fms

Publications (1)

Publication Number Publication Date
AU2006291007A1 true AU2006291007A1 (en) 2007-03-22

Family

ID=37672228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006291007A Abandoned AU2006291007A1 (en) 2005-09-14 2006-09-13 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

Country Status (8)

Country Link
EP (1) EP1937681A1 (fr)
JP (1) JP2009507924A (fr)
KR (1) KR20080045279A (fr)
CN (2) CN101305000A (fr)
AU (1) AU2006291007A1 (fr)
BR (1) BRPI0615838A2 (fr)
CA (1) CA2622725A1 (fr)
WO (1) WO2007033232A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
WO2008055013A2 (fr) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms
CN101821266B (zh) 2007-09-14 2014-03-12 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
GB0919274D0 (en) * 2009-11-03 2009-12-16 Univ The Glasgow Plasma generation apparatus and use of plasma generation apparatus
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
PE20140580A1 (es) * 2011-05-27 2014-06-01 Bayer Ip Gmbh Sintesis quiral de n-{3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]-6-metoxifenil}-1-[2,3-dihidroxi-propil]ciclopropanosulfonamidas
CN103435608A (zh) * 2013-08-22 2013-12-11 中国药科大学 吡啶并嘧啶类plk1抑制剂及其用途
WO2018124001A1 (fr) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Composé inhibiteur de signal bmp
CN111848613B (zh) * 2020-08-11 2021-09-24 山东大学 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用
WO2023125812A1 (fr) * 2021-12-31 2023-07-06 上海海雁医药科技有限公司 Dérivé de pyrimidone substitué, composition pharmaceutique et utilisation médicale de celui-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1053668C (zh) * 1994-06-14 2000-06-21 大日本制药株式会社 新型化合物及其制法和抗肿瘤剂
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
JP4965021B2 (ja) * 1997-08-20 2012-07-04 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
CA2385769A1 (fr) * 1999-09-17 2001-03-22 Gavin C. Hirst Inhibiteurs de kinase utilises comme agents therapeutiques
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone

Also Published As

Publication number Publication date
EP1937681A1 (fr) 2008-07-02
WO2007033232A1 (fr) 2007-03-22
BRPI0615838A2 (pt) 2011-05-31
CN101305000A (zh) 2008-11-12
KR20080045279A (ko) 2008-05-22
CA2622725A1 (fr) 2007-03-22
JP2009507924A (ja) 2009-02-26
CN101300258A (zh) 2008-11-05

Similar Documents

Publication Publication Date Title
US7642270B2 (en) 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
AU2006291007A1 (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
US10344031B2 (en) Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors
US20080114007A1 (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
CA3009669C (fr) Inhibiteurs de la tyrosine kinase de bruton
NO329350B1 (no) 2-(pyridin-2-ylamino)-pyrido(2,3d)pyrimidin-7-on samt anvendelse derav
CZ2001503A3 (cs) Deriváty 1H-imidazopyridinu
CA3056726A1 (fr) Composes tricycliques destines a etre utilises dans le traitement de troubles proliferatifs
US20110046130A1 (en) Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
TWI464170B (zh) ５-酮基-５，８-二氫吡啶并［２，３-ｄ］嘧啶衍生物，其製備及其治療用途
WO2010026113A1 (fr) Acyl- et sufonyl-tétrahydronaphtyridines et dérivés aza de celles-ci en tant qu’antagonistes de récepteur d’histamine h3
WO2010052222A1 (fr) Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine
US7728003B2 (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
WO2004085436A2 (fr) Derives d'acide pyrido[2,3-d]pyrimidine-7-carboxylique, leur fabrication et leur utilisation en tant qu'agents pharmaceutiques
EP2373657A1 (fr) 5, 7-dihydro- 6h-pyrimido ý 5, 4-d¨ý 1¨benzazépin-6-thiones utilisées en tant qu'inhibiteurs de plk
MX2008003685A (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
NZ755300A (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
NZ626306B2 (en) Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors
DE10332232A1 (de) Heteroaryloxy-substituierte Phenylaminopyrimidine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO INCLUDE CO-INVENTOR DESJARLAIS, RENEE

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period